Ovid Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.02
Dividend & YieldN/A$ (N/A)
Beta 1.15
Market capitalization 128.95M
Operating cash flow -58.05M
ESG Scores unknown

Company description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 1.65M -653.95k 14.72M -10.68M
Total Cashflows From Investing Activities -5.36M -30.04M 34.65M -1.82M
Net Borrowings
Total Cash From Financing Activities 286.14k 86.54M 47.07M 904.08k
Change To Operating Activities -2.44M 4.59M 7.1M -6.13M
Issuance Of Stock 286.14k 86.54M 47.24M 925.4k
Net Income -51.98M -60.46M -81.04M 122.83M
Change In Cash -50.64M 5.41M 30.14M 117.69M
Effect Of Exchange Rate
Total Cash From Operating Activities -45.56M -51.09M -51.58M 118.61M
Depreciation 141.73k 255k 306.85k 237.08k
Change To Account Receivables
Other Cashflows From Financing Activities -163.25k -163.25k -163.25k -21.31k
Change To Netincome 7.07M 5.18M 7.33M 12.35M
Capital Expenditures -33.87k -57.16k -127.24k -184.01k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 33.79M 2.39M 63.42M 46.94M
Income Before Tax -51.98M -60.46M -81.04M 124.16M
Net Income -51.98M -60.46M -81.04M 122.83M
Selling General Administrative 19.14M 19.25M 30.63M 37.23M
Gross Profit -39.77M 12.62M 208.38M
Ebit -52.93M -61.41M -81.43M 124.21M
Operating Income -52.93M -61.41M -81.43M 124.21M
Interest Expense
Income Tax Expense 1.33M
Total Revenue 12.62M 208.38M
Cost Of Revenue 39.77M
Total Other Income ExpenseNet 952.07k 948.22k 395.4k -45.69k
Net Income From Continuing Ops -51.98M -60.46M -81.04M 122.83M
Net Income Applicable To Common Shares -51.98M -60.46M -81.04M 119.84M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 8.84M 10.82M 32.29M 14.8M
Total Stockholder Equity 38.81M 70.02M 43.63M 179.75M
Other Current Liabilities 10.8k 4.58M
Total Assets 47.65M 80.84M 75.93M 194.54M
Common Stock 24.65k 54.71k 65.74k 70.36k
Other Current Assets
Retained Earnings -152.7M -213.16M -294.19M -171.36M
Treasury Stock -1.83k 2.47k
Cash 36.49M 41.9M 72.03M 187.8M
Total Current Liabilities 8.84M 10.53M 22.06M 14.8M
Other Stockholder Equity -1.83k 2.47k
Property, Plant, and Equipment 69.87k 68.36k 135.62k 242.76k
Total Current Assets 44.27M 79.81M 74.84M 190.48M
Net Tangible Assets 38.41M 69.56M 43.31M 179.58M
Net Receivables 600.1k 1.13M 141.76k
Accounts Payable 3.76M 3.26M 5.45M 7.13M


Insider Transactions

Here are the insider transactions of stock shares related to Ovid Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
TARDIO JASONSale at price 2.15 per share.D2022-09-12Chief Operating Officer17.34k
RAKHIT AMIT M.D.Sale at price 3.71 per share.D2021-07-14President34.02k
RAKHIT AMIT M.D.Conversion of Exercise of derivative security at price 1.89 per share.D2021-07-14President34.02k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Ovid Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Ovid Therapeutics Inc

Here is the result of two systematic investment strategies applied to Ovid Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Ovid Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Ovid Therapeutics Inc:

Ovid Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -3.92% on the backtest period.

Performance at glance

Performance

-3.92 %

Latent gain

-88.04 $

Invested capital

2247.74 $

Annualized return

-0.95 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Ovid Therapeutics Inc

This is the result of two momentum investment strategies applied to Ovid Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Ovid Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Ovid Therapeutics Inc:

Ovid Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 2.03% of return on Ovid Therapeutics Inc. That represents 96.2$ of latent gain with 4737.25$ of employed capital.
  • The second momentum investment strategy would give 28.17% of return on Ovid Therapeutics Inc. That represents 914.41$ of latent gain with 3246.29$ of employed capital.
Performance at glance (1Q Momentum)

Performance

2.03 %

Latent gain

96.2 $

Invested capital

4737.25 $

Annualized return

13.43 %
Performance at glance (2Q Momentum)

Performance

28.17 %

Latent gain

914.41 $

Invested capital

3246.29 $

Annualized return

7.7 %

Momentum equity curve on Ovid Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Ovid Therapeutics Inc:

Ovid Therapeutics Inc momentum equity

Note: the dividends potentially given by Ovid Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Ovid Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Ovid Therapeutics Inc since the beginning:

Ovid Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Ovid Therapeutics Inc

Buy the dip entry openings on Ovid Therapeutics Inc

Ovid Therapeutics Inc

The performance achieved by the robo-advisor on Ovid Therapeutics Inc is 28.73%. That represents 71.61$ of latent gain with 249.24$ of employed capital. The following chart shows Ovid Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Ovid Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

28.73 %

Latent gain

71.61 $

Invested capital

249.24 $

Annualized return

13.43 %

Equity curve of the strategy applied to Ovid Therapeutics Inc

The following chart shows the result of the investment strategy applied to Ovid Therapeutics Inc:

Ovid Therapeutics Inc

Note: the dividends potentially given by Ovid Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Ovid Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Ovid Therapeutics Inc:

Ovid Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Ovid Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Ovid Therapeutics Inc.

Equity curve comparison on Ovid Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Ovid Therapeutics Inc investment strategy comparison

Employed capital comparison on Ovid Therapeutics Inc

Ovid Therapeutics Inc investment comparison

Performance comparison on Ovid Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -3.92% -88.04$ 2247.74$ -0.95%
Momentum 1 quarter 2.03% 96.2$ 4737.25$ 0.52%
Momentum 2 quarters 28.17% 914.41$ 3246.29$ 7.7%
Non-directional 28.73% 71.61$ 249.24$ 13.43%
Annualized return comparison

Automatic investment

-0.95 %

Momentum 1Q

7.7 %

Momentum 2Q

7.7 %

Non-directional

13.43 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Ovid Therapeutics Inc:

Note: The algorithm computes the probability of correlation between Ovid Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Ovid Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Ovid Therapeutics Inc
Country United States
City New York
Address 1460 Broadway
Phone 646 661 7661
Website www.ovidrx.com
FullTime employees 44
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker OVID
Market www.nasdaq.com

Ovid Therapeutics Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown